At ASCO 2024, Avan J. Armaghani, MD, highlights two key presentations. First, a retrospective study on adjuvant endocrine therapy in ER-low breast cancer (1%-10% ER-positivity) demonstrated that patients who skipped this therapy had significantly worse overall survival, especially those who receiv...
Breast cancer incidence continued an upward trend, rising by 1% annually during 2012–2021,largely confined to localized‐stage and hormone receptor‐positive disease.
它收集并分析癌症发病率、患病率、存活率和国内不同地理区域和人口的治疗模式的数据。 Breast cancer SEER NCI (Surveillance, Epidemiology, and End Results National Cancer Institute) is a program run by the National Cancer Institute in the United States. It collects and analyzes data on cancer incidence...
43P - Efficacy and Safety of Paclitaxel Liposomes in Combination with Anti-HER-2 Targeted Drugs as First-Line Rescue Therapy for HER-2-Positive Locally Advanced or Metastatic Breast Cancer: A Retrospective, Real-World Study Based on the Cancer Database of China National Cancer Center(NCC) 紫杉...
In addition, data on antibody-drug conjugates will be presented, exploring their efficacy alone and in combination with immunotherapy in HER2-negative breast cancer, and research on the role of CDK4/6 inhibitors in HER2-positive breast cancer will be discussed....
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population‐based cancer occurrence and outcomes using incidence data collected by central cancer registries (through 2020) and mortality data collecte...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Dec. 9, 2024-- Four new studies regarding the Breast Cancer Index (BCI) test will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS). Among these studies, initial data will be premiered investigating the potential role of the BCI tes...
日期:2024年9月13日 时间:16:00 - 17:30 主席:Christos Sotiriou (Brussels, Belgium) Karen A. Gelmon (Vancouver, Canada, British Columbia) 地点:Barcelona Auditorium - Hall 2 LBA18 - Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with or...
Current evidence suggests breast‐cancer survivors should also avoid weight gain, be physically active, and eat a healthy diet for overall health. A broad scientific perspective on breast cancer risk requires focus on both environmental exposure to chemicals and health behaviour‐related ...
P3-02-26:Sex-biased cancer cells induce endocrine therapy resistance and immune suppression in male breast cancer 性别偏向性癌细胞在男性乳腺癌中诱导内分泌治疗耐药和免疫抑制 报告作者:Zhishuang Gao P3-02-27:circAXIN1 promotes EMT-mediated metastasis and doxorubicin resistance via Wnt/β-catenin pathwa...